文献速递流行病学与生物统计真实世界研究与卫生经济

随机临床试验中慢性疾病患者的共病与健康相关生活质量:个体参与者数据Meta分析

Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis.
PubMed 文献 · PLoS Med · 2023-01-17

该个体参与者数据Meta分析纳入56项试验(33,421例参与者,16种索引疾病,23类药品),评估共病计数与生活质量的关系。每增加一种共病,EQ-5D基线生活质量更低且随访期间下降(-0.02,95%CI -0.03至-0.01,PBayes>0.999);未发现共病计数与治疗对生活质量疗效之间存在交互作用。

要点

  • 每增加一种共病,EQ-5D基线生活质量更低且随访期间下降(-0.02,95%CI -0.03至-0.01)。
  • SF-36-PCS和SF-36-MCS的关联方向相似,但95%CI跨零(均为-0.05,95%CI -0.10至0.01)。
  • 未发现共病计数与治疗对生活质量疗效之间存在交互作用。

核心结论

  • 在所研究的医学疾病、共病类型和严重程度及基线生活质量水平下,治疗对生活质量的效果未因基线共病计数不同而异,提示临床试验证据可能适用于共病水平(至少中度)更高的情形。

研究设计与样本

  • 纳入在美国试验注册库注册、针对选定索引疾病和药品类别、2/3期或3/4期、样本量≥300例、无严格年龄上限、且于2016年11月21日和2018年5月18日分别可在两个试验数据库之一获取的试验。
  • 124项符合标准,其中56项试验(33,421例参与者,16种索引疾病,23类药品)收集了通用生活质量量表(35项EQ-5D,31项SF-36,其中10项同时收集两者)。
  • 利用两个数据库中可获得个体参与者数据的试验,从病史和/或处方数据计算共病计数,采用线性回归分析共病计数与基线生活质量、随访期间生活质量变化及治疗对生活质量效果的关联,结果在贝叶斯线性模型中合并。
  • 所有结果以标准化单位表示(EQ-5D/SF-36估计值除以已发表的人群标准差),后验样本以均值、2.5th和97.5th百分位数作为可信区间(95%CI)汇总,并以小于0的比例作为负相关概率(PBayes)。
  • 预设方案在PROSPERO注册(CRD42018048202)。

主要发现

  • 每增加一种共病,调整年龄和性别后,在所有索引疾病和治疗比较中,共病计数与基线生活质量更低及随访期间生活质量下降相关(EQ-5D -0.02,95%CI -0.03至-0.01,PBayes>0.999)。
  • SF-36-PCS和SF-36-MCS的关联方向相似,但95%CI跨零(分别为-0.05,95%CI -0.10至0.01,PBayes=0.956;-0.05,95%CI -0.10至0.01,PBayes=0.966)。
  • 未发现共病计数与治疗疗效之间存在交互作用的证据(EQ-5D -0.0035,95%CI -0.0153至-0.0065,PBayes=0.746;SF-36-MCS -0.0111,95%CI -0.0647至0.0416,PBayes=0.70;SF-36-PCS -0.0092,95%CI -0.0758至0.0476,PBayes=0.631)。

临床怎么用

  • 原文结论指出,在所研究的条件下,临床试验证据可能适用于共病水平(至少中度)更高的情形。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Health-related quality of life metrics evaluate treatments in ways that matter to patients, so are often included in randomised clinical trials (hereafter trials). Multimorbidity, where individuals have 2 or more conditions, is negatively associated with quality of life. However, whether multimorbidity predicts change over time or modifies treatment effects for quality of life is unknown. Therefore, clinicians and guideline developers are uncertain about the applicability of trial findings to people with multimorbidity. We examined whether comorbidity count (higher counts indicating greater multimorbidity) (i) is associated with quality of life at baseline; (ii) predicts change in quality of life over time; and/or (iii) modifies treatment effects on quality of life. METHODS AND FINDINGS: Included trials were registered on the United States trials registry for selected index medical conditions and drug classes, phase 2/3, 3 or 4, had ≥300 participants, a nonrestrictive upper age limit, and were available on 1 of 2 trial repositories on 21 November 2016 and 18 May 2018, respectively. Of 124 meeting these criteria, 56 trials (33,421 participants, 16 index conditions, and 23 drug classes) collected a generic quality of life outcome measure (35 EuroQol-5 dimension (EQ-5D), 31 36-item short form survey (SF-36) with 10 collecting both). Blinding and completeness of follow up were examined for each trial. Using trials where individual participant data (IPD) was available from 2 repositories, a comorbidity count was calculated from medical history and/or prescriptions data. Linear regressions were fitted for the association between comorbidity count and (i) quality of life at baseline; (ii) change in quality of life during trial follow up; and (iii) treatment effects on quality of life. These results were then combined in Bayesian linear models. Posterior samples were summarised via the mean, 2.5th and 97.5th percentiles as credible intervals (95% CI) and via the proportion with values less than 0 as the probability (PBayes) of a negative association. All results are in standardised units (obtained by dividing the EQ-5D/SF-36 estimates by published population standard deviations). Per additional comorbidity, adjusting for age and sex, across all index conditions and treatment comparisons, comorbidity count was associated with lower quality of life at baseline and with a decline in quality of life over time (EQ-5D -0.02 [95% CI -0.03 to -0.01], PBayes > 0.999). Associations were similar, but with wider 95% CIs crossing the null for SF-36-PCS and SF-36-MCS (-0.05 [-0.10 to 0.01], PBayes = 0.956 and -0.05 [-0.10 to 0.01], PBayes = 0.966, respectively). Importantly, there was no evidence of any interaction between comorbidity count and treatment efficacy for either EQ-5D or SF-36 (EQ-5D -0.0035 [95% CI -0.0153 to -0.0065], PBayes = 0.746; SF-36-MCS (-0.0111 [95% CI -0.0647 to 0.0416], PBayes = 0.70 and SF-36-PCS -0.0092 [95% CI -0.0758 to 0.0476], PBayes = 0.631. CONCLUSIONS: Treatment effects on quality of life did not differ by multimorbidity (measured via a comorbidity count) at baseline-for the medical conditions studied, types and severity of comorbidities and level of quality of life at baseline, suggesting that evidence from clinical trials is likely to be applicable to settings with (at least modestly) higher levels of comorbidity. TRIAL REGISTRATION: A prespecified protocol was registered on PROSPERO (CRD42018048202).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Butterly EW, Hanlon P, Shah ASV, et al. Comorbidity and health-related quality of life in people with a chronic medical condition in randomised clinical trials: An individual participant data meta-analysis. PLoS Med. 2023. PMID: 36649256. doi:10.1371/journal.pmed.1004154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。